Indivior PLC (IZQVF) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à North Chesterfield, VA, United States. Le PDG actuel est Mark Crossley.
IZQVF a date d'introduction en bourse 2014-12-26, 1,000 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $2.89B.
Indivior PLC is a specialty pharmaceutical company that develops, manufactures, and markets buprenorphine-based prescription medications for treating opioid dependence and related disorders. The company's primary products include SUBLOCADE, an injectable formulation, and SUBOXONE, available in sublingual film and tablet forms, alongside legacy medications such as Temgesic and Buprenex. With operations spanning approximately 40 countries worldwide, Indivior focuses on addressing opioid use disorder, addiction, and co-occurring conditions through its product pipeline. Headquartered in North Chesterfield, Virginia, the company was established in 2014 and maintains research collaborations to advance its therapeutic offerings.
